PRESS RELEASE
For Immediate Release
Philadelphia, PA, USA, March 25, 2023, The GOG Foundation, Inc. (GOG) announced positive results from an investigator-initiated phase II trial, sponsored by the GOG, investigating the combination of ribociclib and letrozole in patients with recurrent low-grade serous ovarian cancer (LGSOC) (GOG-3026). The results were presented at The Society of Gynecologic Oncology’s 2023 Annual Meeting on Women’s Cancer ™ in Tampa, Florida.
Ribociclib and letrozole combination is active in patients with advanced or recurrent LGSOC: Phase II trial results:
- Ribociclib and letrozole is an active combination in LGSOC.
- ORR, PFS, DOR compare favorably to most active agents previously investigated.
In this trial, the reported response rate was 23%, the progression-free survival 19.1 months, and the duration of response of 19.1 months. Sixty-four percent of evaluable patients experienced a reduction in target tumor size.
“These results are promising. Women with this disease have limited treatment options. The progression-free survival and duration of response are both 6 months greater than what we have observed with the current standard treatments,” stated Brian Slomovitz, MD, Professor of Obstetrics/Gynecology and Division Director at Mount Sinai Medical Center in Miami Beach, Florida and the Principal Investigator for this trial.
Click here to view the press release.